Clinical Trial Update: A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial of siltuximab (CNTO 328) in relapsed or refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED